Cargando…

KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer

BACKGROUND: In spite of great progress in the surgical and clinical management, until now no significant improvement in overall survival of High-Grade Serous Ovarian Cancer (HGSOC) patients has been achieved. Important aspects for disease control remain unresolved, including unclear pathogenesis, hi...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Donato, Marta, Babini, Gabriele, Mozzetti, Simona, Buttarelli, Marianna, Ciucci, Alessandra, Arduini, Gloria, De Rosa, Maria Cristina, Scambia, Giovanni, Gallo, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702713/ https://www.ncbi.nlm.nih.gov/pubmed/33250051 http://dx.doi.org/10.1186/s13046-020-01775-9

Ejemplares similares

Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer
por: Buttarelli, Marianna, et al.
Publicado: (2020)

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
por: Raspaglio, Giuseppina, et al.
Publicado: (2023)

Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment
por: Ciucci, Alessandra, et al.
Publicado: (2016)

Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers
por: Ciucci, Alessandra, et al.
Publicado: (2016)

Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients
por: Buttarelli, Marianna, et al.
Publicado: (2022)

Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application
por: Ciucci, Alessandra, et al.
Publicado: (2022)

The relevance of prelamin A and RAD51 as molecular biomarkers in cervical cancer
por: Leonardi, Simona, et al.
Publicado: (2017)

Expression of the Glioma-Associated Oncogene Homolog 1 (Gli1) in Advanced Serous Ovarian Cancer Is Associated with Unfavorable Overall Survival
por: Ciucci, Alessandra, et al.
Publicado: (2013)

What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study
por: Perrone, Emanuele, et al.
Publicado: (2022)

A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer
por: Buttarelli, Marianna, et al.
Publicado: (2019)

The interaction of β-arrestin1 with talin1 driven by endothelin A receptor as a feature of α5β1 integrin activation in high-grade serous ovarian cancer
por: Masi, Ilenia, et al.
Publicado: (2023)

Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma
por: de Cristofaro, Tiziana, et al.
Publicado: (2016)

Identification of candidate genes associated with tubal origin of high-grade serous ovarian cancer
por: Xiang, Li, et al.
Publicado: (2018)

Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer
por: Lu, Haonan, et al.
Publicado: (2021)

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes
por: Hunter, Sally M., et al.
Publicado: (2015)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids
por: Cesari, Eleonora, et al.
Publicado: (2023)

LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma
por: Sato, Sho, et al.
Publicado: (2023)

NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
por: Marchetti, Claudia, et al.
Publicado: (2021)

In search for biomarkers and potential drug targets for uterine serous endometrial cancer
por: Dinoi, Giorgia, et al.
Publicado: (2021)

Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine
por: Nero, Camilla, et al.
Publicado: (2021)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibition
por: Raspaglio, Giuseppina, et al.
Publicado: (2021)

Semiquantitative RT-PCR analysis to assess the expression levels of multiple transcripts from the same sample
por: Marone, Maria, et al.
Publicado: (2001)

Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer
por: Lawrenson, Kate, et al.
Publicado: (2015)

Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes
por: Subramanian, Deepak N., et al.
Publicado: (2020)

Tumour microenvironment‐based molecular profiling reveals ideal candidates for high‐grade serous ovarian cancer immunotherapy
por: Lu, Xiaofan, et al.
Publicado: (2021)

USP19 and RPL23 as Candidate Prognostic Markers for Advanced-Stage High-Grade Serous Ovarian Carcinoma
por: Kang, Haeyoun, et al.
Publicado: (2021)

Machine Learning analysis of high-grade serous ovarian cancer proteomic dataset reveals novel candidate biomarkers
por: Farinella, Federica, et al.
Publicado: (2022)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

Proteome profiling of low grade serous ovarian cancer
por: zadeh fakhar, Haniyeh Bashi, et al.
Publicado: (2019)

High-grade serous ovarian cancer: the clone wars
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2017)

Molecular Management of High-Grade Serous Ovarian Carcinoma
por: Punzón-Jiménez, Paula, et al.
Publicado: (2022)

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma
por: Norris, Eric J, et al.
Publicado: (2019)

Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease
por: Santoro, Angela, et al.
Publicado: (2019)

AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization
por: Azzalini, Eros, et al.
Publicado: (2022)

Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma
por: Ribeiro e Ribeiro, Renan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_imfag5nq2ahih9qea4mfg2seu3